#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Scott Cenci Email
SVP, Information Technology and Digital . Genmab
Copenhagen V,
LocationPrimary Email
How to contact Scott Cenci
Join and see Scott's contact info for free!Phone
Current Roles
Employees:
2784Revenue:
$7.9BAbout
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimerGenmab Address
902 Carnegie CenterCopenhagen V, null
Denmark